leadf
logo-loader
viewOpen Orphan PLC

Open Orphan doses first volunteer with next-generation coronavirus vaccine

The phase I study will take place at the company’s hVIVO’s facility in East London

Open Orphan PLC -
The inoculation is delivered nasally

Open Orphan PLC (LON:ORPH) said the first volunteer has been dosed with a new needle-free, nasally-administered coronavirus (COVID-19) vaccine.

The phase I trial of the next-generation single-dose inoculation will take place at the company’s hVIVO’s facility, a specialist centre for human challenge studies.

The advance has been developed by a US company called Codagenix and will be subject to a randomised, double-blind, placebo-controlled dose-escalation assessment.

This will evaluate the safety and tolerability of the single-dose intranasal vaccine candidate in 48 healthy young adult volunteers at hVIVO's state-of-the-art centre in Whitechapel, London.

"We are delighted to have been chosen by the New York-based Codagenix to run this very important COVID-19 vaccine study in our quarantine clinic in London,” said Open Orphan chairman, Cathal Friel in a statement.  

“This vaccine is one of the first of the next generation COVID-19 vaccines, it is a single dose, needle-free, intranasal, live attenuated COVID-19 virus vaccine. Thus, in our opinion, because it is a live attenuated virus vaccine, COVI-VAC has the potential to give much longer-lasting cellular immunity against COVID-19 than many of the first-generation vaccines.”

Friel said Codagenix sought an inpatient facility for the first-in-human evaluation “to allow for a thorough evaluation of product safety and real-time volunteer monitoring.”

“Our unique state-of-the-art quarantine facility in East London is one of the few facilities in the world suitable to conduct this trial safely and successfully,” he added.

Quick facts: Open Orphan PLC

Price: 29 GBX

AIM:ORPH
Market: AIM
Market Cap: £194.13 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Open Orphan PLC named herein, including the promotion by the Company of Open Orphan PLC in any Content on the Site, the Company receives from...

FOR OUR FULL DISCLAIMER CLICK HERE

Open Orphan to become '$1bln firm in very near future' after COVID-19 study...

Open Orphan PLC's (LON:ORPH) Cathal Friel talks to Proactive London's Katie Pilbeam about the world’s first COVID-19 characterisation study receiving approval from a specially convened Research Ethics Committee (REC).  This follows a contract received by the company’s subsidiary hVIVO...

2 weeks, 6 days ago

2 min read